Group 1 - Triangle Defense signed a gas turbine project development and framework order agreement with Siemens Energy [1] - The development agreement allows Triangle Defense to qualify for supplying specific items to Siemens Energy, detailing technical prerequisites and standards [1] - Triangle Defense specializes in the research, production, and sales of forged products in aviation, aerospace, and shipping industries [1] Group 2 - Aerospace Hongtu was suspended from military procurement for three years due to alleged violations during a procurement activity [2] - The suspension will last from July 6, 2024, to July 6, 2027, affecting the company's participation in military material procurement [2] - Aerospace Hongtu focuses on satellite operations and data collection [3] Group 3 - Kaili Medical's executives purchased a total of 460,000 shares, investing approximately 13.15 million yuan [4] - The average purchase prices were 28.70 yuan and 28.53 yuan per share [4] - Kaili Medical is engaged in the research, production, and sales of medical diagnostic and treatment equipment [5] Group 4 - Muyuan Foods reported a 22.28% year-on-year decline in sales revenue from live pigs in October, totaling 10.33 billion yuan [6] - The average selling price of live pigs decreased by 32.73% year-on-year to 11.55 yuan per kilogram [6] - Muyuan Foods is involved in pig farming and slaughtering [7] Group 5 - Niuwei Co. plans to acquire 40% of its subsidiary Dongwu Machinery for 139 million yuan, aiming for full ownership [8] - Niuwei Co. specializes in the research, manufacturing, and sales of industrial valves [9] Group 6 - Jinlong Automobile reported a 14.71% year-on-year decline in bus sales in October, with 4,121 units sold [10] - Jinlong Automobile focuses on the production and sales of bus products [10] Group 7 - ST Tianshan reported a 242.54% year-on-year increase in sales revenue from live livestock in October, totaling 13.35 million yuan [11] - The company sold 1,367 head of livestock, marking a significant increase compared to previous periods [11] - ST Tianshan is involved in the breeding and sales of cattle and dairy products [12] Group 8 - Ningbo Port expects a 12.4% year-on-year increase in container throughput in October, reaching 4.56 million TEUs [13] - The total cargo throughput is projected to be 99.6 million tons, a 5.3% increase year-on-year [13] - Ningbo Port engages in port handling and logistics services [13] Group 9 - Amcare Pharma received approval for supplementary drug applications and clinical trials for its products [14] - The company is focused on new drug development and utilizes a MAH model for production [14] Group 10 - Lude Environment plans to change its stock name to "Lude Technology" while keeping its full name and stock code unchanged [15] - The company specializes in waste treatment and resource utilization technologies [15] Group 11 - Hualan Co. plans to increase its stake in the company by investing between 30 million and 60 million yuan [16] - The maximum purchase price is set at 58.08 yuan per share [16] - Hualan Co. focuses on the development and sales of packaging materials for injectable drugs [16] Group 12 - Caina Co. is using 140 million yuan of idle funds to purchase structured deposits from a bank, with expected annual yields between 0.70% and 1.85% [17] - Caina Co. specializes in the research, production, and sales of injection and laboratory consumables [17] Group 13 - Zhenghong Technology reported a 52.80% year-on-year decrease in sales revenue from live pigs in October, totaling 4.32 million yuan [18] - The company sold 400 head of pigs, marking a significant decline compared to previous periods [18] - Zhenghong Technology is involved in feed production and pig farming [18] Group 14 - Caida Securities received approval from the CSRC to issue bonds totaling up to 6 billion yuan [19] - The company is engaged in securities brokerage, investment banking, and asset management [19] Group 15 - Jiayuan Technology signed a copper foil supply framework agreement with CATL, establishing a long-term partnership [20] - The agreement includes collaboration in the supply and production of materials for new battery technologies [20] Group 16 - Haikong Group announced the resignation of its general manager due to personal career planning [21] - The company is involved in automotive passenger transport and related services [21] Group 17 - Beizhi Technology's application to acquire 100% of Suzhou Suike Intelligent Technology has been accepted by the Shanghai Stock Exchange [22] - The company specializes in intelligent logistics systems and equipment [22] Group 18 - Yikang Pharma's subsidiary received approval for clinical trials of a new injection for chronic hepatitis B [23] - The company focuses on the production and sales of raw and formulated pharmaceutical products [23] Group 19 - Hengyuan Coal Power plans to acquire 100% of two coal companies for 440 million yuan [24] - The acquisition includes assuming debts totaling 1.137 billion yuan [24] - Hengyuan Coal Power is involved in coal mining and sales [24] Group 20 - Yangpu Medical announced the cancellation of a production arrangement for a medical device [25] - The company specializes in precision medical and testing services [25] Group 21 - Kailong High-Tech plans to establish a 195 million yuan industry fund focusing on unlisted companies [26] - The company is involved in air pollution control and new energy management systems [26] Group 22 - Yingli Co. received approval for its application to acquire a majority stake in a company [27] - The company specializes in precision electronic components and related manufacturing [27] Group 23 - Tianyi Medical's arterial-venous puncture device received EU MDR certification, valid until January 2028 [28] - The company focuses on medical devices for blood purification and care [28] Group 24 - Chuangyuan Co. appointed a new president, effective until the end of the current board term [29] - The company specializes in the design and production of paper products [29] Group 25 - Shanghai Laishi's new indication for a drug received clinical trial approval [30] - The company focuses on the production and sales of blood products [30] Group 26 - Fengmao Co. plans to issue convertible bonds to raise up to 520 million yuan for expansion and working capital [31] - The company specializes in precision rubber components [31] Group 27 - Yinuo Si's shareholder plans to transfer 3% of the company's shares through an inquiry process [32] - The company provides comprehensive R&D services in the biopharmaceutical sector [32] Group 28 - Phoenix Shipping plans to use up to 50 million yuan of idle funds for cash management [33] - The company is involved in dry bulk shipping and logistics services [33] Group 29 - Xingyuan Zhuomei received a notification to supply magnesium alloy components worth 2.021 billion yuan to a new energy vehicle manufacturer [34] - The project is expected to start mass production in the third quarter of 2026 [34] Group 30 - Landai Technology's subsidiary plans to sell electric drive assembly assets for 110 million yuan [35] - The company specializes in power transmission and display technology [35] Group 31 - Yuexiu Capital plans to distribute a cash dividend of 0.90 yuan per share [36] - The company is involved in asset management and private equity [36] Group 32 - Northeast Securities plans to distribute a cash dividend of 1.00 yuan per share, totaling 234 million yuan [37] - The company focuses on wealth management and investment banking [37] Group 33 - Jinguang Electric won a bid for a project from the State Grid worth 21.7976 million yuan [38] - The company specializes in the research and manufacturing of power distribution equipment [39] Group 34 - Huarong Co. plans to repurchase shares worth between 40 million and 125 million yuan [40] - The company focuses on the production and sales of explosion-proof electrical equipment [40] Group 35 - Baiyang Pharma signed a distribution agreement for a blood product, gaining exclusive rights in specific markets [41] - The company specializes in the development and commercialization of medical innovations [41] Group 36 - Li Qun Co.'s director plans to reduce his stake by up to 71,000 shares due to personal financial needs [42] - The company is involved in retail and logistics services [42] Group 37 - Su Li Co.'s shareholder plans to reduce his stake by up to 0.48% of the company's shares [43] - The company specializes in the production and sales of fine chemical products [43] Group 38 - Shenzhen Ruijie obtained a commitment letter for a stock repurchase loan of up to 15.3 million yuan [44] - The company provides project management and evaluation services [44] Group 39 - Fudan Zhangjiang's shareholder plans to reduce his stake by up to 1% of the company's shares [45] - The company focuses on biopharmaceutical research and development [45] Group 40 - Ningbo Zhongbai's shareholder plans to reduce his stake by up to 1% of the company's shares [46] - The company is involved in retail and wholesale operations [46] Group 41 - Jingyi Co. announced a change in control due to a judicial auction of shares [47] - The company specializes in copper processing and digital carbon services [47] Group 42 - Luoping Zinc Electric's subsidiary obtained a new safety production license for mining operations [48] - The company focuses on hydropower and mining activities [48]

Shareholder Reduction Plans - Zhongjing Technology's shareholder Longi Green Energy plans to reduce holdings by no more than 3.8764 million shares [1] - Guobo Electronics' shareholder China Electronics Technology Group plans to reduce holdings by no more than 2.00% [1] - Hongbai New Materials' shareholder Xinyu Baolong plans to reduce holdings by no more than 19.5 million shares [1] - Founder Securities' shareholder China Cinda plans to reduce holdings by no more than 82.321 million shares [1] - Ningbo Zhongbai's shareholder Zhang Jiangbo plans to reduce holdings by no more than 1% [1] - Suli Co., Ltd.'s shareholder Gusheng Investment plans to reduce holdings by no more than 900,000 shares [1] - Ruihua Tai's shareholder Hangke New Century plans to reduce holdings by no more than 180,000 shares [1] - Shenkong's shareholder More Liangzhao plans to reduce holdings by no more than 2% [1] Other Notable Events - Yao Yigou received a tax matter notification [1] - ST Lingnan is being prosecuted for alleged collusion in bidding [1]

Core Viewpoint - The major shareholder of Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. plans to reduce his shareholding due to personal financial needs, with a maximum reduction of 10,365,721 shares, representing up to 1.00% of the company's total share capital [3][4]. Shareholder Information - As of the announcement date, Mr. Yang Zongmeng holds 64,009,773 shares, accounting for 6.18% of the company's total share capital. These shares were released from restrictions on June 19, 2023 [2][3]. Reduction Plan Details - Mr. Yang plans to reduce his holdings through centralized bidding within three months after 15 trading days from the announcement date. The minimum selling price will not be lower than the adjusted price of 8.64 yuan per share, considering any corporate actions that may affect the share price [3][4][5]. - The reduction plan is consistent with previous commitments made by Mr. Yang regarding shareholding and reduction methods [5][6]. Compliance and Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange's rules [6][7]. - The company and its shareholders will adhere to disclosure obligations throughout the reduction process [7].

Core Viewpoint - Fudan Zhangjiang (688505.SH) announced that Mr. Yang Zongmeng plans to reduce his shareholding in the company due to personal funding needs, intending to sell up to 10,365,721 shares, which represents a maximum of 1.00% of the company's total share capital [1] Group 1 - Mr. Yang Zongmeng will initiate the share reduction 15 trading days after the announcement [1] - The planned reduction will occur within a three-month period [1] - The method of share reduction will be through centralized bidding [1]

Core Insights - On November 4, six A-share listed companies disclosed share buybacks, including Huakai Yibai, Midea Group, and Ningde Times [1] - Seventeen A-share listed companies announced share reductions, including Yinghe Technology and Tianhe Solar [1] Buyback Summary - Huakai Yibai: Director Zhuang Junchao plans to buy back at least 30 million yuan worth of shares [2] - Midea Group: Has repurchased A-shares totaling 9.575 billion yuan [2] - Qingyue Technology: Actual controller Gao Yudi proposed a buyback of 10 million to 20 million yuan [2] - Shenzhen Ruijie: Obtained a commitment letter for a special loan for stock buyback [2] - Ningde Times: As of October 31, has repurchased 15.9908 million shares for a total amount of 4.386 billion yuan [2] - Huarong Co.: Plans to buy back shares worth 40 million to 125 million yuan [2] Reduction Summary - Yinghe Technology: Director Wang Jun plans to reduce holdings by no more than 2,700 shares [2] - Shenzhou Information: Shareholder Shen Chang Technology has completed the reduction of 9.5 million shares [2] - Tianhe Solar: Youze Venture Capital reduced holdings by 12.4749 million shares from September 5 to November 3 [2] - Hongbai New Materials: Shareholder Xinyu Baolong plans to reduce no more than 3% of shares [2] - Guobo Electronics: Shareholder Zhongdian Ke Guomi plans to reduce no more than 2% of shares [2] - Aorite: Shareholder Tiantai Boren plans to reduce no more than 0.25% of shares [2] - Yinuosi: Shareholder Zhangjiang Biomedical Base plans to transfer 4.2294 million shares, accounting for 3% of total equity [2] - Founder Securities: Third-largest shareholder China Cinda plans to reduce no more than 1% of shares [2] - Nine Company: Depository receipt holders plan to reduce no more than 0.04% of depository receipts [2] - Ningbo Zhongbai: Shareholder Zhang Jiangbo plans to reduce no more than 1% of shares [2] - Fudan Zhangjiang: Shareholder Yang Zongmeng plans to reduce no more than 1% of shares [2] - Liqun Co.: Director and executive Hu Peifeng plans to reduce no more than 0.08% of shares [2] - Suli Co.: Shareholder Jiesheng Investment plans to reduce no more than 0.48% of shares [2] - Shengkong Co.: Shareholder More Light plans to reduce no more than 2% of shares [2] - Ruihua Tai: Shareholder Hangke New Century plans to reduce no more than 1% of shares [2] - Shentong Technology: Directors Wang Huan and Zhou Baocong plan to reduce no more than 0.0473% of shares [2] - Huapei Niuwu: Shareholder Guoshou Chengda plans to reduce no more than 2% of shares [2]

Summary of Key Points Core Viewpoint - Several shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership dynamics within the market [1]. Group 1: Shareholder Reductions - Hongbo New Materials' shareholder, Xinyu Baolong, intends to reduce its stake by 3% [1]. - Dayilong's shareholder, Lefeng Investment, has reduced its stake by 3% [1]. - Ningbo Zhongbai's Zhang Jiangbo plans to reduce his stake by 1% [1]. - Founder Securities reports that China Cinda plans to reduce its stake by 1% within three months [1]. - Liqun Co., Ltd.'s director, Hu Peifeng, intends to reduce his stake by 0.08% [1]. - Suli Co., Ltd.'s Guosheng Investment plans to reduce its stake by 0.4816% [1]. - Jinzhen Co., Ltd.'s Zhao Jian and Xu Minbo have reduced their stakes by 0.98% and 0.11%, respectively [1]. - Shenkong Technology's Wang Huan and Zhou Baocong plan to reduce their stakes by up to 0.0263% and 0.0210% within three months [1]. - Huaxi Biological's shareholder, Guoshou Chengda, plans to reduce its stake by no more than 2% [1]. - Xuanta Pharmaceutical's Qihe Venture has reduced its stake by 0.7098% [1]. - Desheng Technology's actual controller, Guo Xiaobin, has reduced his stake by 0.51% [1]. - Liren Technology's Liren Investment has reduced its stake by 0.0779% [1]. Group 2: Shareholder Increases - Zhongju Gaoxin's Li Ruxiong has increased his stake by 0.0129% [1].

一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-037 上海复旦张江生物医药股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 召开日期时间：2025 年 11 月 26 日 13 点 00 分 召开地点：上海市浦东新区张江高科技园区蔡伦路 308 号 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 26 日 至2025 年 11 月 26 日 股东大会召开日期：2025年11月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票 ...

上海复旦张江生物医药股份有限公司 2025 年第一次临时股东大会 会议资料 二〇二五年十一月 | 会议须知 | 1 | | --- | --- | | 会议议程 | 3 | | 会议议案 | 5 | | 议案 1：《关于变更部分募集资金投资项目的议案》 | 5 | | 议案 2：《关于修订<公司章程>及取消监事会的议案》 | 17 | | 议案 3：《关于修订<股东大会议事规则>的议案》 | 19 | | 议案 4：《关于修订<董事会议事规则>的议案》 | 20 | | 附件一：《公司章程》修订对照表 | 21 | | 附件二：《股东大会议事规则》修订对照表 | 80 | | 附件三：《董事会议事规则》修订对照表 | 96 | 上海复旦张江生物医药股份有限公司 2025 年第一次临时股东大会 会议须知 为了维护全体股东的合法权益、保障股东依法行使股东权利，确保股东大会 的正常秩序和议事效率，根据《中华人民共和国公司法》《中华人民共和国证券 法》、中国证监会《上市公司股东会规则》以及《上海复旦张江生物医药股份有 限公司章程》及《上海复旦张江生物医药股份有限公司股东大会议事规则》等有 关规定，特制订本须知。 一、 ...

截至本公告披露日，上海复旦张江生物医药股份有限公司（以下简称"公司" 或"复旦张江"）股东杨宗孟先生持有公司股份 64,009,773 股，占公司总股本的 6.18%。杨宗孟先生所持有的公司股份来源为公司首次公开发行前取得的股份， 该部分股份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 减持计划的主要内容 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-038 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 公司于近日收到杨宗孟先生发来的《关于减持复旦张江股份计划的告知函》， 因自身资金需求，杨宗孟先生计划自本公告披露之日起 15 个交易日后的 3 个月 内通过集中竞价的方式减持公司股份不超过 10,365,721 股，拟减持比例不超过公 司总股本的 1.00%。 根据杨宗孟先生于《复旦张江首次公开发行股票并在科创板上市招股说明书》 作出的承诺："本人减持所持有公 ...

Core Viewpoint - Fudan Zhangjiang (688505.SH) announced that Mr. Yang Zongmeng plans to reduce his shareholding in the company due to personal funding needs, intending to sell up to 10.3657 million shares, which represents no more than 1% of the company's total share capital [1] Summary by Category - **Shareholding Reduction Plan** - Mr. Yang Zongmeng intends to reduce his holdings through centralized bidding within three months after a 15 trading day notice period [1] - The maximum number of shares to be sold is 10.3657 million [1] - The planned reduction will not exceed 1% of the total share capital of the company [1]